The active agent in the nasal spray, 2-bromopalmitate, carries a high risk of interfering with a number of processes, making ...

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

While food and lifestyle changes can't completely reverse the effects of Alzheimer's disease, your plate could go a long way ...

To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...

The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

Researchers have uncovered how certain genetic mutations lead to unique spherical amyloid plaques in inherited forms of ...

Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...